AIMOVIG® (erenumab) prescribing information (external link)
KESIMPTA®▼ (ofatumumab) prescribing information (external link)
MAYZENT® (siponimod) prescribing information (external link)
This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.
Neuroscience
AIMOVIG® (erenumab)
KESIMPTA®▼ (ofatumumab)
KESIMPTA (ofatumumab) demonstration pen injections; Dr David Paling & Joela Matthews
KESIMPTA (ofatumumab): Data from pivotal trials; Professor Eli Silber
Professor Eli Silber presents the efficacy data from two pivotal clinical trials, highlighting the importance of starting patients on high-efficacy therapies from the outset.
KESIMPTA (ofatumumab): King’s College Hospital real-own experience; Professor Eli Silber
Professor Eli Silber explains how the King’s College Hospital regional hub and spoke model operates, which enables the review of ~30 cases every 2 weeks.
KESIMPTA (ofatumumab): St George’s Hospital real-own experience; Sarah White
Lead MS Clinical Nurse Specialist Sarah White presents her real own experience at St George’s, highlighting the importance of shared decision-making.
Learnings on how KESIMPTA (ofatumumab) impacted services at St George’s; Sarah White
Lead MS Clinical Nurse Specialist Sarah White shares the lessons learnt since implementing KESIMPTA and how it has impacted the MS service at St George’s Hospital.
KESIMPTA (ofatumumab): UK and worldwide patient exposure; Professor Eli Silber
Professor Eli Silber examines patient data to show how real-world use of KESIMPTA has grown since launch, and emphasises the importance of timely initiation.
Considerations when choosing a disease-modifying therapy: the changing landscape; Professor Eli Silber
Professor Eli Silber discusses various considerations when choosing a DMT, including disease severity, risk, resources and reimbursement.
How can Pharmacy support the NHS Recovery plan using KESIMPTA as the case study; Joela Mathews
Joela Mathews, Lead Neuroscience Pharmacist, highlights how KESIMPTA offers an alternative way of managing RMS patients and supporting the capacity challenge.
Patient journey: How KesimptaConnect can support your patients
Patient “Voice”: Perspectives on KesimptaConnect
HCP interviews: KesimptaConnect Real World Experience
MAYZENT® (siponimod)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
